

## HA130 Disposable Hemoperfusion Cartridge Properties

Adsorbent Volume(mL)	130
Biocompatibility	Tested as required in ISO10993
Adsorbent Material	Double Cross-linked Styrene-divinylbenzene Copolymers
Housing Material	Polycarbonate
Sterilization Method	Irradiation Sterilization
Unit Package	195±2mm(L)*110±2mm(w)*110.5±2mm(H)

\*Contraindications, Warnings and Precautions refer to Instructions For Use.


## JAFRON - Global Manufacturer and Supplier of Adsorption Columns



Jafron Headquarters



CE



ISO 9001



EN ISO 13485

### References

- [1] Shun-Jie Chen, et al. Int J Artif Organs 2011; 34 (4): 339-347.
- [2] Yang Xiaodan, Continuing Medical Education, March. 2019, Vol. 33, No.3.
- [3] Guo Ai-hua, et al. Journal of Clinical Rehabilitative Tissue Engineering Research March 19, 2011 Vol.15, No.12.
- [4] Jing Zhang, et al. Int J Clin Exp Med 2016;9(5):8563-8568.
- [5] Yu Yin, et al. Journal of Hainan Medical University (2015)57-60.
- [6] Li-ying Miao, et al. Experimental And Therapeutic Medicine 7: 947-952, 2014.
- [7] Yan Hong Gu, et al. The International Journal of Artificial Organs 1-7, 2019.
- [8] Zhu Feng, et al. Chinese and Foreign Medical Research Vol.17, No.6 February, 2019.
- [9] Duan Bin, et al. Med J West China, February 2019, Vol. 31, No.2.
- [10] He Qi, et al. Chinese Journal of Clinical Research, February 2018, Vol. 31, No.2.
- [11] Zhang Yu, et al. Shanghai Medicine, November 2018, Vol.39, No.21.
- [12] Yu Jirong, et al. J Southeast Univ(Med Sci Edi) Dec. 2018, Vol.37, No.6:1018-1022.
- [13] Jun Tang, et al. Journal of Hainan Medical University 2017; 23(4): 74-78.
- [14] Li Xiaolei, et al. Journal of Practical Medicine 2017, 33(20).
- [15] Ji Xu, et al. Journal of Internal Intensive Medicine 2017, 23(3).
- [16] Pomarè Montin, et al. Blood Purif 2018;46:187-195.

**Jafron**

Stock Abbreviation: JFSW  
Stock Code: 300529

# HD/HDF+HP

## Remove Uremic Toxins<sup>[1-16]</sup>



CY-HA130-01-10-2021-EN

# HA130 Disposable Hemoperfusion Cartridge

20 years in blood purification clinical practices  
Widely used in more than 80 countries  
More than 5 million treatments per year

CE 0197

(For Internal Use)



**JAFRON BIOMEDICAL CO., LTD.**

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.

Tel: +86 (756) 3689708

E-mail: overseatrade@jafron.com

Website: www.jafron.com



With the development of blood purification, complications are still main problems for ESRD patients due to the accumulation of middle molecules and protein-bound uremic toxins.

HA130 hemoperfusion therapy provides a new regimen for ESRD complications.

## Adsorption Therapy Applications<sup>△</sup>

According to clinical practices, hemoperfusion therapy can be applied in the listed conditions.




Toxins and Related Complications

## HA130 Disposable Hemoperfusion Cartridge used in series with dialyzer


- Removal of **middle molecules and protein-bound uremic toxins** and amelioration of symptoms of the **ESRD complications**.
- **20 years'** clinical practices, applications in **8000+ hospitals** with over **5 million** treatments annually.
- **Flexible** compatibility with various blood purification machines and therapies such as HD, HDF, and CRRT.

## Efficiency & Safety



Neutral macroporous 3D adsorptive resin could adsorb middle and protein-bound uremic toxins

- High mechanical strength of adsorbents
- Large adsorptive surface area
- Accurate adjustment of pore size distribution



Good biocompatibility<sup>[16]</sup>

- Advanced coating method
- Optimized hemodynamics

With particle filter

- Prevent particle detachment into human body


<sup>△</sup>For detailed information, please visit [www.jafron.com](http://www.jafron.com).

## Combined Artificial Kidney: HD/HDF+HP

With the adsorptive capability of removing uremic toxins, HD/HDF+HP provides a new therapy to remove uremic toxins in ESRD.




Advanced Technology · Simple Operation




## HD+HP Provides a New Blood Purification Therapy for ESRD


### Remove Toxins<sup>[1]</sup>



### Relieve Dialysis Complications<sup>[7,9]</sup>



### Improve Life Quality and Survival Rate<sup>[1]</sup>



\* Compared to Control group, P<0.05